Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8372315 | 0.94 | ALDH1A1 (0.47) | DRD2DRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL2780770 | 0.93 | KDM4E (0.53) | DRD2DRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL4299909 | 0.91 | MEN1 (0.54) | DRD2DRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL1677141 | 0.88 | ALDH1A1 (0.60) | DRD2DRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL555384 | 0.88 | ALDH1A1 (0.56) | DRD3CYP2D6L3MBTL1ALDH1A1HRH3 | |
| SCHEMBL10338308 | 0.85 | MEN1 (0.60) | DRD2DRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL9114592 | 0.83 | CYP1A2 (0.63) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL10877820 | 0.83 | LTA4H (0.54) | DRD2DRD4DRD3KDM4ESMN1; SMN2 | |
| SCHEMBL1620167 | 0.81 | APP (0.52) | DRD2DRD4DRD3MEN1LMNA | |
| SCHEMBL2719251 | 0.81 | ALDH1A1 (0.56) | SMN1; SMN2CYP1A2CYP2D6CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010065024-A1 | TOPICAL TREATMENT OF CATARACTS IN DOGS | KADOR PETER F (US) | 2010-06-10 | — | — | WO | claimed |
| US-20090082415-A1 | Topical treatment of cataracts in dogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2009-03-26 | — | — | US | claimed |
| EP-0206611-B1 | 3-(4-FLUOROPHENOXY)-1-PROPANOL | PFIZER INC. (US) | 1989-03-01 | — | — | EP | claimed |
| EP-0206611-A2 | 3-(4-Fluorophenoxy)-1-Propanol | PFIZER INC. (US) | 1986-12-30 | — | — | EP | claimed |
| WO-1986007353-A1 | INTERMEDIATE IN THE PRODUCTION OF AN ASYMMETRIC HYDANTOIN | PFIZER INC. (US) | 1986-12-18 | — | — | WO | claimed |
| US-11377434-B2 | Methods for preparing substituted chromanone derivatives | HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) | 2022-07-05 | — | — | US | disclosed |
| US-20220024890-A1 | METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES | HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| WO-2022016309-A1 | METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES | HANGZHOU DUYI TECHNOLOGY CO. LTD. (CN) | 2022-01-27 | — | — | WO | disclosed |
| US-11187980-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-11-30 | — | — | US | disclosed |
| US-20200073237-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-03-05 | — | — | US | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| EP-0206611-B1 | 3-(4-FLUOROPHENOXY)-1-PROPANOL | PFIZER INC. (US) | 1989-03-01 | — | — | EP | disclosed |
| EP-0206611-B1 | 3-(4-FLUOROPHENOXY)-1-PROPANOL | PFIZER INC. (US) | 1989-03-01 | — | — | EP | disclosed |
| EP-0206611-A3 | 3-(4-FLUOROPHENOXY)-1-PROPANOL | — | 1987-09-02 | — | — | EP | disclosed |
| EP-0206611-A2 | 3-(4-Fluorophenoxy)-1-Propanol | PFIZER INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0206611-A2 | 3-(4-Fluorophenoxy)-1-Propanol | PFIZER INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| EP-0206611-A2 | 3-(4-Fluorophenoxy)-1-Propanol | PFIZER INC. (US) | 1986-12-30 | — | — | EP | disclosed |
| WO-1986007353-A1 | INTERMEDIATE IN THE PRODUCTION OF AN ASYMMETRIC HYDANTOIN | PFIZER INC. (US) | 1986-12-18 | — | — | WO | disclosed |
| WO-1986007353-A1 | INTERMEDIATE IN THE PRODUCTION OF AN ASYMMETRIC HYDANTOIN | PFIZER INC. (US) | 1986-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082415-A1 | Topical treatment of cataracts in dogs | AKR1A1, AKR1B1, AKR1C1 | DRD2 3738/4885DRD4 4111/4885DRD3 4444/4885 |
| US-20220024890-A1 | METHODS FOR PREPARING SUBSTITUTED CHROMANONE DERIVATIVES | CBR3, CYP2F1, CBR1 | DRD2 1698/4885DRD4 937/4885DRD3 1103/4885 |
| US-11377434-B2 | Methods for preparing substituted chromanone derivatives | CYP2E1, CYP2F1, CBR1 | DRD2 1871/4885DRD4 1030/4885DRD3 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.